1 January 2024 – 30 June 2024 (unaudited)
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2024 |
302 |
203,129 |
21,832 |
-10,393 |
1,217 |
165,139 |
381,226 |
|
|
|
|
|
|
|
|
|
|
Result for the period |
|
|
|
|
|
-11,386 |
-11,386 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
-1,964 |
-1,964 |
|
Currency exchange differences |
|
|
-8,709 |
|
|
|
-8,709 |
|
Total comprehensive income |
– |
– |
-8,709 |
– |
– |
-13,350 |
-22,059 |
|
|
|
|
|
|
|
|
|
|
Share-based payment |
|
|
|
|
750 |
|
750 |
|
Transfer of own shares |
|
|
|
1,028 |
-1,028 |
|
– |
|
Total transactions with owners |
– |
– |
– |
1,028 |
-278 |
– |
750 |
|
Balance as at 30 June 2024 |
302 |
203,129 |
13,123 |
-9,365 |
939 |
151,789 |
359,917 |
1 January 2023 – 30 June 2023 (unaudited)
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2023 |
302 |
203,129 |
14,119 |
-13,609 |
3,590 |
214,146 |
421,677 |
|
|
|
|
|
|
|
|
|
|
Result for the period |
|
|
|
|
|
-34,266 |
-34,266 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
2,231 |
2,231 |
|
Currency exchange differences |
|
|
-5,720 |
|
|
|
-5,720 |
|
Total comprehensive income |
– |
– |
-5,720 |
– |
– |
-32,035 |
-37,755 |
|
|
|
|
|
|
|
|
|
|
Share-based payment |
|
|
|
|
393 |
|
393 |
|
Transfer of own shares |
|
|
|
1,327 |
-1,327 |
|
– |
|
Total transactions with owners |
– |
0 |
– |
1,327 |
-934 |
– |
393 |
|
Balance as at 30 June 2023 |
302 |
203,129 |
8,399 |
-12,282 |
2,656 |
182,111 |
384,315 |